The European growth buyout investor intends to expand the use of the firm’s expertise in non-invasive breath analysis devices.
European growth buyout investor Keensight Capital has acquired a majority stake in Bedfont Scientific, a company that designs and manufactures non-invasive breath analysis medical devices.
Financial terms have not been disclosed.
As part of the transaction, the company’s existing shareholders will reinvest alongside Keensight.
With a track record in both medtech and the respiratory field, Keensight intends to use its expertise and network to support Bedfont’s next stage of growth. Previous investments include orthobiologics firm Isto Biologics, health IT software provider Interoperability Group, and medical laboratory software provider Finbiosoft.
“Bedfont is a highly innovative company whose pioneering work in breath biomarkers, particularly fractional exhaled nitric oxide, is helping to advance global standards in respiratory diagnostics,” said Keensight partner Amit Karna.
Founded in 1976 and headquartered in Maidstone, Bedfont is a leader in non-invasive breath analysis devices, supporting not only medical diagnosis but also the monitoring and management of respiratory and metabolic conditions. The company designs and manufactures high-precision breath and gas analysis instruments, with a particular focus on biomarkers for asthma diagnosis and management.
